ClinicalTrials.gg
CompletedNCT04100018CheckMate 7DXUpdated Jun 12, 2025Results posted

A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer

A Phase 3 interventional study of Nivolumab and Prednisone in Prostate Cancer, sponsored by Bristol-Myers Squibb. Completed at 293 sites in 28 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-12.

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,030
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 23 studies testing nivolumab in Prostatic Neoplasms — 1 open to participants now, 9 under way, none of them phase 3. Nivolumab · Prostatic Neoplasms.

Enrollment
2nd of 23
1,030 · median 45
Started
2020
with 3 others
Phase 3
Only one
of the 23
Registered
17th of 23
by date
Lead sponsor
4 of 23
Bristol-Myers Squibb

Among the 23 studies testing nivolumab in Prostatic Neoplasms, this one is the 2nd largest by enrollment, is one of 4 that started in 2020, is the only one in phase 3, and was the 17th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,579 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

1 of the 23 studies testing nivolumab in Prostatic Neoplasms is open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About nivolumab

Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,228 Prostatic Neoplasms studies recruiting now, 927 (75%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing nivolumab in Prostatic Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety and effectiveness of nivolumab with docetaxel in men with advanced castration resistant prostate cancer who have progressed after second-generation hormonal manipulation.

03

Conditions studied

  • Prostate Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histologic confirmation of adenocarcinoma of the prostate without small cell features
  • Current evidence of disease documented by either bone lesions on radionuclide bone scan and/or soft tissue lesions on computerized tomography/magnetic resonance imaging (CT/MRI)
  • (ECOG) performance status 0-1
  • Ongoing androgen deprivation therapy (ADT) with a gonadotropin-releasing hormone (GnRH) analogue or bilateral orchiectomy
  • Documented prostate cancer progression per Prostate Cancer Working Group (PCWG3) criteria within 6 months prior to screening
  • Chemotherapy-naïve for metastatic castration-resistant prostate cancer (mCRPC), with 1 to 2 prior second generation hormonal therapies in the recurrent non-metastatic setting and/or metastatic setting, and no more than 1 second generation hormonal therapy in the mCRPC setting. Must have progressed during or after second generation hormonal therapy or have documented intolerance to second generation hormonal therapy
  • Participants must meet one of the following criteria regarding tissue submission: Sufficient tumor samples from a newly obtained ("fresh") (obtained during screening); or archival tumor tissue in the form of formalin-fixed paraffin-embedded (FFPE) block or unstained tumor tissue slides. For participants with bone-only disease or inaccessible soft tissue lesions or if the biopsy procedure would pose an unacceptable clinical risk for the participant, submission of tumor tissue obtained from a fresh biopsy is not required.
  • Men must agree to follow specific methods of , if applicable

Exclusion criteria

Exclusion Criteria:

  • Active
  • Active, known, or suspected disease
  • Condition requiring systemic treatment with (> 10 mg daily prednisone equivalent) or other medications within 14 days of start of study treatment. Inhaled or topical steroids or adrenal replacement steroid doses are permitted in the absence of active autoimmune disease
  • Prior treatment with an , anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways
  • Prior treatment with docetaxel or other chemotherapy for mCRPC. Prior docetaxel for castration-sensitive prostate cancer is permitted if at least 12 months have elapsed from last dose of docetaxel

Other protocol-defined inclusion/exclusion criteria apply

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,030 participants (actual)

Study arms

  • Experimental
    Arm A: Nivolumab + docetaxel + prednisone

    Biological: Nivolumab · Drug: Prednisone · Drug: Docetaxel

  • Placebo comparator
    Arm B: Placebo + docetaxel + prednisone

    Drug: Prednisone · Drug: Docetaxel · Other: Placebo

Interventions

  • BiologicalNivolumab

    Specified dose on specified days

    Also known as: OPDIVO,, BMS-936558-01

  • Specified dose on specified days

  • Specified dose on specified days

  • OtherPlacebo

    Specified dose on specified days

06

What researchers measure

Primary outcomes

  1. Radiographic Progressive Free Survival (rPFS) Assessed by Blinded Independent Central Review (BICR) Per Prostate Cancer Working Group 3 (PCWG3)

    rPFS for randomized participants is the time between randomization and the first date of documented progression or death due to any cause, whichever occurs first. The rPFS was censored at the last radiographic tumor assessment up to the start of subsequent cancer therapy for those without progression or death. It was also censored at the date of last radiographic tumor assessment prior to the missed tumor assessments for participants who had progressive disease (PD) or death immediately after more than one consecutive missed tumor assessments. Radiographic progression is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 millimeter (mm). The appearance of one or more new lesions is also considered progression.

    Time frame: from randomization to the first date of documented progression or death due to any cause, whichever occurs first (up to approximately 31 months)

  2. Overall Survival (OS)

    OS for all randomized participants is the time between randomization and the date of death from any cause. For participants who are alive, their survival time was censored at the last date that they were known to be alive. OS was censored for participants at the date of randomization if they had no follow-up.

    Time frame: From randomization to the date of death from any cause (Up to approximately 31 months)

Secondary outcomes

  1. Objective Response Rate (ORR) Assessed by Blinded Independent Central Review (BICR) Per Prostate Cancer Working Group (PCWG3)

    Objective Response Rate per PCWG3 (ORR-PCWG3) is the percentage of participants who have a confirmed complete or partial best overall response (BOR) per PCWG3 among randomized participants who have measurable disease at baseline. Complete Response (CR) is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Partial Response (PR) is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Baseline was defined as evaluations or events that occur before the date and time of the first dose of study treatment or evaluations on the same date and time of the first dose of study treatment were also considered as baseline evaluations.

    Time frame: From date of randomization to the date of objectively documented progression per PCWG3 or the date of subsequent systemic cancer therapy, whichever occurs first (Up to approximately 52 months)

  2. Time to Response (TTR) Assessed by Blinded Independent Central Review (BICR) Per Prostate Cancer Working Group (PCWG3)

    Time to Response per PCWG3 (TTR-PCWG3) is the time from randomization to the date of the first documented CR or PR per PCWG3, as determined by BICR. Complete Response (CR) is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Partial Response (PR) is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: From randomization to the date of the first documented CR or PR (Up to approximately 52 months)

  3. Duration of Response Assessed by Blinded Independent Central Review (BICR) Per Prostate Cancer Working Group (PCWG3)

    Duration of Response per PCWG3 (DOR-PCWG3) is time between the date of first response (CR/PR per PCWG3) to the date of first documented radiographic progression per PCWG3,as determined by BICR, or death due to any cause whichever occurs first. Complete Response (CR) is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Partial Response (PR) is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Radiographic progression was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 millimeter (mm). The appearance of one or more new lesions is also considered progression.

    Time frame: From randomization date to the date of first documented radiographic progression or death due to any cause whichever occurs first (Up to approximately 52 months)

  4. Prostate-specific Antigen (PSA) Response Rate (PSA-RR)

    PSA Response Rate (PSA-RR) is the percentage of randomized participants with a 50% or greater decrease in PSA from baseline to the lowest post-baseline PSA result. A second consecutive value obtained 3 or more weeks later is required to confirm the PSA response. Baseline was defined as valuations or events that occur before the date and time of the first dose of study treatment or evaluations on the same date and time of the first dose of study treatment were also considered as baseline evaluations.

    Time frame: Up to approximately 52 months

  5. Time to PSA Progression (TTP-PSA)

    Time to PSA Progression (TTP-PSA) is the time between randomization to the date of PSA progression per PCWG3 in randomized participants. PSA Progression: For participants with an initial PSA decline from baseline, the date of PSA progression is the date that an increase of 25% or more and an absolute increase of 2 ng/mL or more from the nadir are documented and confirmed by a second consecutive PSA value at least 3 weeks later. For participants with no PSA decline from baseline, the date of PSA progression is date that an increase of 25% or more and an absolute increase of 2 ng/mL or more from baseline are documented at or beyond Week 13. Baseline was defined as valuations or events that occur before the date and time of the first dose of study treatment or evaluations on the same date and time of the first dose of study treatment were also considered as baseline evaluations. Censored at date of last PSA evaluation on/prior to start of subsequent cancer therapy.

    Time frame: from randomization to the date of PSA Progression (Up to approximately 31 months)

  6. Number of Participants With Adverse Events

    An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment.

    Time frame: From first dose and 30 days after last dose of study therapy (Up to approximately 25 months)

  7. Number of Participants With Serious Adverse Events

    Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose results in death or Is life-threatening or requires inpatient hospitalization or causes prolongation of existing hospitalization or results in persistent or significant disability/incapacity or is a congenital anomaly/birth defect.

    Time frame: From first dose and 30 days after last dose of study therapy (Up to approximately 25 months)

  8. Number of Participants With Adverse Events Leading to Discontinuation

    An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment.

    Time frame: From first dose and 30 days after last dose of study therapy (Up to approximately 25 months)

  9. Number of Participants With Endocrine Immune-Mediated Adverse Events

    Immune-mediated adverse events are AEs consistent with an immune-mediated mechanism or immune-mediated component for which non-inflammatory etiologies (eg, infection or tumor progression) have been ruled out. IMAEs can include events with an alternate etiology which were exacerbated by the induction of autoimmunity. An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment.

    Time frame: From first dose and 100 days after last dose of study therapy (Up to approximately 13 months)

  10. Number of Participants With Non-Endocrine Immune-Mediated Adverse Events

    Immune-mediated adverse events are AEs consistent with an immune-mediated mechanism or immune-mediated component for which non-inflammatory etiologies (eg, infection or tumor progression) have been ruled out. IMAEs can include events with an alternate etiology which were exacerbated by the induction of autoimmunity. An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment.

    Time frame: From first dose and 100 days after last dose of study therapy (Up to approximately 13 months)

  11. Number of Participants With Select Adverse Events

    An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment.

    Time frame: From first dose and 30 days after last dose of study therapy (Up to approximately 25 months)

  12. Number of Participants Who Died

    Time frame: Up to approximately 52 months

  13. Number of Participants With Worst Common Terminology Criteria (CTC) Grade Laboratory Test Grade Change From Baseline

    The severity of laboratory test results were graded based upon the participants symptoms according to the Common Terminology Criteria for Adverse Events (CTCAE, Version 5.0); Hematology parameters were evaluated for severity according to the following scale: Grade 0 is defined as absence of an AE or within normal limits; Grade 1 = Mild - transient or mild discomfort; no medical intervention required; Grade 2 = Moderate - mild to moderate limitation in activity; Grade 3 = Severe; Grade 4 = Life threatening. Number of participants with worst grade change results to Grade 3 or Grade 4 laboratory test results is presented. E.g., the row title HEMOGLOBIN Grade 0 to Grade 3, Grade 0 is baseline and Grade 3 is post baseline.

    Time frame: From first dose and 30 days after last dose of study therapy (Up to approximately 25 months)

  14. Number of Participants With Laboratory Abnormalities in Specific Thyroid Tests

    Blood samples were collected for conducting specific thyroid test. Baseline is defined as evaluations or events that occur before the date and time of the first dose of study treatment. Baseline was defined as evaluations or events that occur before the date and time of the first dose of study treatment or evaluations on the same date and time of the first dose of study treatment were also considered as baseline evaluations.

    Time frame: From first dose and 30 days after last dose of study therapy (Up to approximately 11 months)

  15. Time to Pain Progression as Assessed by Brief Pain Inventory-Short Form (BPI-SF)

    The BPI-SF is an instrument to assess pain and includes severity and interference scores. BPI-SF is an 11-item self-report questionnaire designed to assess severity and impact of pain on daily function. Participants rate severity of pain at its "worst," "least," and "average" in last 24 hours using an 11-point numerical rating scale with anchors of "no pain" and "pain as bad. The participant's assessment of pain with BPI-SF Item number 3 (pain symptoms at their worst over the last 24 hours) form basis for analysis. Time to pain progression is time between date of randomization and date of first increase in worst pain intensity. Pain progression occurred if an increase in worst pain intensity of \>= 2 points is observed from baseline and maintained over 2 consecutive time periods. Baseline was evaluations or events that occur before date and time of first dose of study treatment or evaluations on same date and time of first dose of study treatment were also considered as baseline.

    Time frame: From randomization to 1st pain symptoms at their worst over the last 24 hours (Up to approximately 31 months

07

Results

Posted Jul 22, 2024

Participant flow

Pre-Treatment Period
Participant flow — Pre-Treatment Period
MilestoneNivolumab + Docetaxel + PrednisonePlacebo + Docetaxel + Prednisone
Started514516
Completed510510
Not completed46
Withdrew: Not reported04
Withdrew: Subject no longer meets study criteria11
Withdrew: Poor/non-compliance10
Withdrew: Participant withdrew consent20
Withdrew: Participant request to discontinue study treatment01
Treatment Period
Participant flow — Treatment Period
MilestoneNivolumab + Docetaxel + PrednisonePlacebo + Docetaxel + Prednisone
Started510510
Completed1911
Not completed491499
Withdrew: Ongoing treatment10
Withdrew: Other reason2637
Withdrew: Completed treatment as per protocol12
Withdrew: Maximum clinical benefit30
Withdrew: Adverse event unrelated to study drug1312
Withdrew: Study drug toxicity6728
Withdrew: Disease progression284327
Withdrew: Administrative reasons by sponsor1630
Withdrew: Poor/non-compliance10
Withdrew: Lost to follow-up22
Withdrew: Death1611
Withdrew: Participant withdrew consent1010
Withdrew: Participant request to discontinue study treatment3332
Withdrew: Adverse event146
Withdrew: Lack of efficacy42

Outcome measures

PrimaryRadiographic Progressive Free Survival (rPFS) Assessed by Blinded Independent Central Review (BICR) Per Prostate Cancer Working Group 3 (PCWG3)

rPFS for randomized participants is the time between randomization and the first date of documented progression or death due to any cause, whichever occurs first. The rPFS was censored at the last radiographic tumor assessment up to the start of subsequent cancer therapy for those without progression or death. It was also censored at the date of last radiographic tumor assessment prior to the missed tumor assessments for participants who had progressive disease (PD) or death immediately after more than one consecutive missed tumor assessments. Radiographic progression is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 millimeter (mm). The appearance of one or more new lesions is also considered progression.

Time frame:
from randomization to the first date of documented progression or death due to any cause, whichever occurs first (up to approximately 31 months)
Reported as:
Median · months
Radiographic Progressive Free Survival (rPFS) Assessed by Blinded Independent Central Review (BICR) Per Prostate Cancer Working Group 3 (PCWG3)
monthsNivolumab + Docetaxel + PrednisonePlacebo + Docetaxel + Prednisone
Radiographic Progressive Free Survival (rPFS) Assessed by Blinded Independent Central Review (BICR) Per Prostate Cancer Working Group 3 (PCWG3)9.43 (8.48 to 10.32)8.74 (8.38 to 9.99)
Statistical analysis
  • Nivolumab + Docetaxel + Prednisone vs Placebo + Docetaxel + Prednisone · Log Rank · p = 0.5901 (Boundary for statistical significance p-value \< 0.01) · Cox proportional hazard: 0.96 · 99% CI 0.77 to 1.19Stratification factor is visceral disease (YES vs NO) as entered in the IRT.
PrimaryOverall Survival (OS)

OS for all randomized participants is the time between randomization and the date of death from any cause. For participants who are alive, their survival time was censored at the last date that they were known to be alive. OS was censored for participants at the date of randomization if they had no follow-up.

Time frame:
From randomization to the date of death from any cause (Up to approximately 31 months)
Reported as:
Median · months
Overall Survival (OS)
monthsNivolumab + Docetaxel + PrednisonePlacebo + Docetaxel + Prednisone
Overall Survival (OS)18.73 (16.95 to 21.03)18.92 (17.31 to 22.01)
Statistical analysis
  • Nivolumab + Docetaxel + Prednisone vs Placebo + Docetaxel + Prednisone · Log Rank · p = 0.3572 (Boundary for statistical significance p-value \< 0.0059. Additional accuracy for p-value: 0.005866.) · Cox proportional hazard: 1.09 · 99.41% CI 0.84 to 1.43Stratification factor is visceral disease (YES vs NO) as entered in the IRT.
SecondaryObjective Response Rate (ORR) Assessed by Blinded Independent Central Review (BICR) Per Prostate Cancer Working Group (PCWG3)

Objective Response Rate per PCWG3 (ORR-PCWG3) is the percentage of participants who have a confirmed complete or partial best overall response (BOR) per PCWG3 among randomized participants who have measurable disease at baseline. Complete Response (CR) is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Partial Response (PR) is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Baseline was defined as evaluations or events that occur before the date and time of the first dose of study treatment or evaluations on the same date and time of the first dose of study treatment were also considered as baseline evaluations.

Time frame:
From date of randomization to the date of objectively documented progression per PCWG3 or the date of subsequent systemic cancer therapy, whichever occurs first (Up to approximately 52 months)
Reported as:
Number · percentage of participants
Objective Response Rate (ORR) Assessed by Blinded Independent Central Review (BICR) Per Prostate Cancer Working Group (PCWG3)
percentage of participantsNivolumab + Docetaxel + PrednisonePlacebo + Docetaxel + Prednisone
Objective Response Rate (ORR) Assessed by Blinded Independent Central Review (BICR) Per Prostate Cancer Working Group (PCWG3)27.3 (21.5 to 33.8)23.5 (17.9 to 30.0)
Statistical analysis
  • Nivolumab + Docetaxel + Prednisone vs Placebo + Docetaxel + Prednisone · Adjusted difference: 3.8 · 95% CI -4.5 to 12.1Strata adjusted difference in objective response rate based on DerSimonian and Laird method. Stratified by visceral disease (YES vs NO) as entered in the IRT.
SecondaryTime to Response (TTR) Assessed by Blinded Independent Central Review (BICR) Per Prostate Cancer Working Group (PCWG3)

Time to Response per PCWG3 (TTR-PCWG3) is the time from randomization to the date of the first documented CR or PR per PCWG3, as determined by BICR. Complete Response (CR) is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Partial Response (PR) is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
From randomization to the date of the first documented CR or PR (Up to approximately 52 months)
Reported as:
Median · months
Time to Response (TTR) Assessed by Blinded Independent Central Review (BICR) Per Prostate Cancer Working Group (PCWG3)
monthsNivolumab + Docetaxel + PrednisonePlacebo + Docetaxel + Prednisone
Time to Response (TTR) Assessed by Blinded Independent Central Review (BICR) Per Prostate Cancer Working Group (PCWG3)2.17 (1.4 to 7.8)2.20 (1.7 to 8.2)
SecondaryDuration of Response Assessed by Blinded Independent Central Review (BICR) Per Prostate Cancer Working Group (PCWG3)

Duration of Response per PCWG3 (DOR-PCWG3) is time between the date of first response (CR/PR per PCWG3) to the date of first documented radiographic progression per PCWG3,as determined by BICR, or death due to any cause whichever occurs first. Complete Response (CR) is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Partial Response (PR) is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Radiographic progression was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 millimeter (mm). The appearance of one or more new lesions is also considered progression.

Time frame:
From randomization date to the date of first documented radiographic progression or death due to any cause whichever occurs first (Up to approximately 52 months)
Reported as:
Median · months
Duration of Response Assessed by Blinded Independent Central Review (BICR) Per Prostate Cancer Working Group (PCWG3)
monthsNivolumab + Docetaxel + PrednisonePlacebo + Docetaxel + Prednisone
Duration of Response Assessed by Blinded Independent Central Review (BICR) Per Prostate Cancer Working Group (PCWG3)8.31 (6.18 to 10.15)8.11 (6.34 to 8.74)
SecondaryProstate-specific Antigen (PSA) Response Rate (PSA-RR)

PSA Response Rate (PSA-RR) is the percentage of randomized participants with a 50% or greater decrease in PSA from baseline to the lowest post-baseline PSA result. A second consecutive value obtained 3 or more weeks later is required to confirm the PSA response. Baseline was defined as valuations or events that occur before the date and time of the first dose of study treatment or evaluations on the same date and time of the first dose of study treatment were also considered as baseline evaluations.

Time frame:
Up to approximately 52 months
Reported as:
Number · percentage of participants
Prostate-specific Antigen (PSA) Response Rate (PSA-RR)
percentage of participantsNivolumab + Docetaxel + PrednisonePlacebo + Docetaxel + Prednisone
Prostate-specific Antigen (PSA) Response Rate (PSA-RR)42.4 (38.0 to 46.8)41.6 (37.2 to 46.0)
Statistical analysis
  • Nivolumab + Docetaxel + Prednisone vs Placebo + Docetaxel + Prednisone · Percentage difference: 0.9 · 95% CI -5.2 to 7.0Strata adjusted difference in objective response rate based on DerSimonian and Laird method. Stratified by visceral disease (YES vs NO) as entered in the IRT.
SecondaryTime to PSA Progression (TTP-PSA)

Time to PSA Progression (TTP-PSA) is the time between randomization to the date of PSA progression per PCWG3 in randomized participants. PSA Progression: For participants with an initial PSA decline from baseline, the date of PSA progression is the date that an increase of 25% or more and an absolute increase of 2 ng/mL or more from the nadir are documented and confirmed by a second consecutive PSA value at least 3 weeks later. For participants with no PSA decline from baseline, the date of PSA progression is date that an increase of 25% or more and an absolute increase of 2 ng/mL or more from baseline are documented at or beyond Week 13. Baseline was defined as valuations or events that occur before the date and time of the first dose of study treatment or evaluations on the same date and time of the first dose of study treatment were also considered as baseline evaluations. Censored at date of last PSA evaluation on/prior to start of subsequent cancer therapy.

Time frame:
from randomization to the date of PSA Progression (Up to approximately 31 months)
Reported as:
Median · months
Time to PSA Progression (TTP-PSA)
monthsNivolumab + Docetaxel + PrednisonePlacebo + Docetaxel + Prednisone
Time to PSA Progression (TTP-PSA)6.28 (5.82 to 6.97)6.21 (5.65 to 6.77)
Statistical analysis
  • Nivolumab + Docetaxel + Prednisone vs Placebo + Docetaxel + Prednisone · Cox proportional hazard: 1.00 · 95% CI 0.86 to 1.16Stratification factor is visceral disease (YES vs NO) as entered in the IRT.
SecondaryNumber of Participants With Adverse Events

An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment.

Time frame:
From first dose and 30 days after last dose of study therapy (Up to approximately 25 months)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events
ParticipantsNivolumab + Docetaxel + PrednisonePlacebo + Docetaxel + Prednisone
Number of Participants With Adverse Events501503
SecondaryNumber of Participants With Serious Adverse Events

Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose results in death or Is life-threatening or requires inpatient hospitalization or causes prolongation of existing hospitalization or results in persistent or significant disability/incapacity or is a congenital anomaly/birth defect.

Time frame:
From first dose and 30 days after last dose of study therapy (Up to approximately 25 months)
Reported as:
Count of participants · Participants
Number of Participants With Serious Adverse Events
ParticipantsNivolumab + Docetaxel + PrednisonePlacebo + Docetaxel + Prednisone
Number of Participants With Serious Adverse Events223192
SecondaryNumber of Participants With Adverse Events Leading to Discontinuation

An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment.

Time frame:
From first dose and 30 days after last dose of study therapy (Up to approximately 25 months)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events Leading to Discontinuation
ParticipantsNivolumab + Docetaxel + PrednisonePlacebo + Docetaxel + Prednisone
Number of Participants With Adverse Events Leading to Discontinuation148101
SecondaryNumber of Participants With Endocrine Immune-Mediated Adverse Events

Immune-mediated adverse events are AEs consistent with an immune-mediated mechanism or immune-mediated component for which non-inflammatory etiologies (eg, infection or tumor progression) have been ruled out. IMAEs can include events with an alternate etiology which were exacerbated by the induction of autoimmunity. An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment.

Time frame:
From first dose and 100 days after last dose of study therapy (Up to approximately 13 months)
Reported as:
Count of participants · Participants
Number of Participants With Endocrine Immune-Mediated Adverse Events
ParticipantsNivolumab + Docetaxel + PrednisonePlacebo + Docetaxel + Prednisone
Adrenal insufficiency74
Hypothyroidism2711
Thyroiditis10
Diabetes mellitus12
Diabetic ketoacidosis10
Type 1 diabetes mellitus10
Hyperthyroidism2011
Immune-mediated hypophysitis10
Hypopituitarism01
SecondaryNumber of Participants With Non-Endocrine Immune-Mediated Adverse Events

Immune-mediated adverse events are AEs consistent with an immune-mediated mechanism or immune-mediated component for which non-inflammatory etiologies (eg, infection or tumor progression) have been ruled out. IMAEs can include events with an alternate etiology which were exacerbated by the induction of autoimmunity. An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment.

Time frame:
From first dose and 100 days after last dose of study therapy (Up to approximately 13 months)
Reported as:
Count of participants · Participants
Number of Participants With Non-Endocrine Immune-Mediated Adverse Events
ParticipantsNivolumab + Docetaxel + PrednisonePlacebo + Docetaxel + Prednisone
Pneumonitis152
Interstitial lung disease51
Immune-mediated lung disease10
Diarrhoea82
Colitis40
Enterocolitis10
Alanine aminotransferase increased50
Aspartate aminotransferase increased30
Hypertransaminasaemia30
Autoimmune hepatitis20
Immune-mediated hepatitis20
Blood bilirubin increased10
Cholangitis10
Blood creatinine increased10
Acute kidney injury01
Immune-mediated nephritis01
Rash147
Rash maculo-papular30
Rash pustular20
Dermatitis11
Dermatitis acneiform10
Drug eruption10
Pemphigoid10
Erythema multiforme01
Immune-mediated dermatitis01
Rash macular01
Infusion related reaction33
Hypersensitivity01
Infusion related hypersensitivity reaction01
SecondaryNumber of Participants With Select Adverse Events

An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment.

Time frame:
From first dose and 30 days after last dose of study therapy (Up to approximately 25 months)
Reported as:
Count of participants · Participants
Number of Participants With Select Adverse Events
ParticipantsNivolumab + Docetaxel + PrednisonePlacebo + Docetaxel + Prednisone
Diarrhoea176159
Colitis72
Enterocolitis21
Frequent bowel movements01
Alanine aminotransferase increased3614
Aspartate aminotransferase increased2615
Blood alkaline phosphatase increased2322
Blood bilirubin increased84
Gamma-glutamyltransferase increased53
Hepatic cytolysis41
Transaminases increased41
Autoimmune hepatitis20
Cholangitis20
Hyperbilirubinaemia22
Hypertransaminasaemia20
Hepatic enzyme increased12
Hepatitis10
Immune-mediated hepatitis10
Liver injury10
Liver disorder01
Pneumonitis266
Interstitial lung disease74
Acute respiratory failure10
Immune-mediated lung disease10
Lung infiltration10
Idiopathic interstitial pneumonia01
Blood creatinine increased227
Acute kidney injury79
Renal failure35
Blood urea increased22
Immune-mediated nephritis01
Rash5134
Pruritus4720
Eczema103
Rash maculo-papular116
Dermatitis64
Palmar-plantar erythrodysaesthesia syndrome522
Urticaria53
Erythema411
Psoriasis43
Skin exfoliation42
Dermatitis acneiform31
Rash macular32
Dermatitis allergic20
Rash erythematous22
Rash pustular30
Vitiligo21
Blister10
Dermatitis atopic12
Dermatitis exfoliative10
Drug eruption10
Erythema multiforme11
Exfoliative rash10
Pemphigoid10
Photosensitivity reaction10
Rash papular11
Rash pruritic10
Immune-mediated dermatitis01
Infusion related reaction2227
Hypersensitivity64
Anaphylactic reaction10
Anaphylactic shock10
Bronchospasm01
Infusion related hypersensitivity reaction03
SecondaryNumber of Participants Who Died
Time frame:
Up to approximately 52 months
Reported as:
Count of participants · Participants
Number of Participants Who Died
ParticipantsNivolumab + Docetaxel + PrednisonePlacebo + Docetaxel + Prednisone
Number of Participants Who Died258227
SecondaryNumber of Participants With Worst Common Terminology Criteria (CTC) Grade Laboratory Test Grade Change From Baseline

The severity of laboratory test results were graded based upon the participants symptoms according to the Common Terminology Criteria for Adverse Events (CTCAE, Version 5.0); Hematology parameters were evaluated for severity according to the following scale: Grade 0 is defined as absence of an AE or within normal limits; Grade 1 = Mild - transient or mild discomfort; no medical intervention required; Grade 2 = Moderate - mild to moderate limitation in activity; Grade 3 = Severe; Grade 4 = Life threatening. Number of participants with worst grade change results to Grade 3 or Grade 4 laboratory test results is presented. E.g., the row title HEMOGLOBIN Grade 0 to Grade 3, Grade 0 is baseline and Grade 3 is post baseline.

Time frame:
From first dose and 30 days after last dose of study therapy (Up to approximately 25 months)
Reported as:
Count of participants · Participants
Number of Participants With Worst Common Terminology Criteria (CTC) Grade Laboratory Test Grade Change From Baseline
ParticipantsNivolumab + Docetaxel + PrednisonePlacebo + Docetaxel + Prednisone
HEMOGLOBIN Grade 0 to Grade 353
HEMOGLOBIN Grade 0 to Grade 4NANA
HEMOGLOBIN Grade 1 to Grade 32016
HEMOGLOBIN Grade 1 to Grade 4NANA
HEMOGLOBIN Grade 2 to Grade 31111
HEMOGLOBIN Grade 2 to Grade 4NANA
HEMOGLOBIN Grade 3 to Grade 300
HEMOGLOBIN Grade 3 to Grade 4NANA
PLATELET COUNT Grade 0 to Grade 323
PLATELET COUNT Grade 0 to Grade 401
PLATELET COUNT Grade 1 to Grade 321
PLATELET COUNT Grade 1 to Grade 411
PLATELET COUNT Grade 2 to Grade 300
PLATELET COUNT Grade 2 to Grade 400
PLATELET COUNT Grade 3 to Grade 300
PLATELET COUNT Grade 3 to Grade 400
PLATELET COUNT Grade 4 to Grade 300
PLATELET COUNT Grade 4 to Grade 400
LEUKOCYTES Grade 0 to Grade 33028
LEUKOCYTES Grade 0 to Grade 41113
LEUKOCYTES Grade 1 to Grade 353
LEUKOCYTES Grade 1 to Grade 411
LEUKOCYTES Grade 2 to Grade 301
LEUKOCYTES Grade 2 to Grade 400
LEUKOCYTES Grade 3 to Grade 300
LEUKOCYTES Grade 3 to Grade 400
LEUKOCYTES Grade 4 to Grade 300
LEUKOCYTES Grade 4 to Grade 400
LYMPHOCYTES Grade 0 to Grade 32217
LYMPHOCYTES Grade 0 to Grade 411
LYMPHOCYTES Grade 1 to Grade 32422
LYMPHOCYTES Grade 1 to Grade 431
LYMPHOCYTES Grade 2 to Grade 31930
LYMPHOCYTES Grade 2 to Grade 422
LYMPHOCYTES Grade 3 to Grade 31019
LYMPHOCYTES Grade 3 to Grade 424
LYMPHOCYTES Grade 4 to Grade 300
LYMPHOCYTES Grade 4 to Grade 400
ANC Grade 0 to Grade 31816
ANC Grade 0 to Grade 44439
ANC Grade 1 to Grade 300
ANC Grade 1 to Grade 401
ANC Grade 2 to Grade 301
ANC Grade 2 to Grade 401
ANC Grade 3 to Grade 300
ANC Grade 3 to Grade 400
ANC Grade 4 to Grade 300
ANC Grade 4 to Grade 400
ALP Grade 0 to Grade 351
ALP Grade 0 to Grade 400
ALP Grade 1 to Grade 311
ALP Grade 1 to Grade 400
ALP Grade 2 to Grade 300
ALP Grade 2 to Grade 400
ALP Grade 3 to Grade 400
ALP Grade 4 to Grade 300
ALP Grade 4 to Grade 400
AMT Grade 0 to Grade 360
AMT Grade 0 to Grade 410
AMT Grade 1 to Grade 312
AMT Grade 1 to Grade 411
AMT Grade 2 to Grade 300
AMT Grade 2 to Grade 400
AMT Grade 3 to Grade 300
AMT Grade 3 to Grade 400
AMT Grade 4 to Grade 300
AMT Grade 4 to Grade 400
ALT Grade 0 to Grade 372
ALT Grade 0 to Grade 430
ALT Grade 1 to Grade 300
ALT Grade 1 to Grade 400
ALT Grade 2 to Grade 300
ALT Grade 3 to Grade 300
ALT Grade 4 to Grade 300
ALT Grade 4 to Grade 400
BILIRUBIN Grade 0 to Grade 321
BILIRUBIN Grade 0 to Grade 410
BILIRUBIN Grade 1 to Grade 300
BILIRUBIN Grade 1 to Grade 400
BILIRUBIN Grade 2 to Grade 300
BILIRUBIN Grade 2 to Grade 400
BILIRUBIN Grade 3 to Grade 300
BILIRUBIN Grade 3 to Grade 400
BILIRUBIN Grade 4 to Grade 300
BILIRUBIN Grade 4 to Grade 400
CREATININE Grade 0 to Grade 344
CREATININE Grade 0 to Grade 400
CREATININE Grade 1 to Grade 310
CREATININE Grade 1 to Grade 410
CREATININE Grade 2 to Grade 301
CREATININE Grade 2 to Grade 410
CREATININE Grade 3 to Grade 300
CREATININE Grade 3 to Grade 400
CREATININE Grade 4 to Grade 300
CREATININE Grade 4 to Grade 400
HYPERNATREMIA Grade 0 to Grade 300
HYPERNATREMIA Grade 0 to Grade 400
HYPERNATREMIA Grade 1 to Grade 300
HYPERNATREMIA Grade 1 to Grade 400
HYPERNATREMIA Grade 2 to Grade 300
HYPERNATREMIA Grade 2 to Grade 400
HYPERNATREMIA Grade 3 to Grade 300
HYPERNATREMIA Grade 3 to Grade 400
HYPERNATREMIA Grade 4 to Grade 300
HYPERNATREMIA Grade 4 to Grade 400
HYPONATREMIA Grade 0 to Grade 354
HYPONATREMIA Grade 0 to Grade 401
HYPONATREMIA Grade 1 to Grade 300
HYPONATREMIA Grade 1 to Grade 401
HYPONATREMIA Grade 2 to Grade 300
HYPONATREMIA Grade 2 to Grade 400
HYPONATREMIA Grade 3 to Grade 300
HYPONATREMIA Grade 3 to Grade 400
HYPONATREMIA Grade 4 to Grade 300
HYPONATREMIA Grade 4 to Grade 400
HYPERKALEMIA Grade 0 to Grade 381
HYPERKALEMIA Grade 0 to Grade 421
HYPERKALEMIA Grade 1 to Grade 320
HYPERKALEMIA Grade 1 to Grade 401
HYPERKALEMIA Grade 2 to Grade 310
HYPERKALEMIA Grade 2 to Grade 400
HYPERKALEMIA Grade 3 to Grade 300
HYPERKALEMIA Grade 3 to Grade 400
HYPERKALEMIA Grade 4 to Grade 300
HYPERKALEMIA Grade 4 to Grade 400
HYPOKALEMIA Grade 0 to Grade 378
HYPOKALEMIA Grade 0 to Grade 410
HYPOKALEMIA Grade 1 to Grade 331
HYPOKALEMIA Grade 1 to Grade 400
HYPOKALEMIA Grade 2 to Grade 300
HYPOKALEMIA Grade 2 to Grade 400
HYPOKALEMIA Grade 3 to Grade 300
HYPOKALEMIA Grade 3 to Grade 400
HYPOKALEMIA Grade 4 to Grade 300
HYPOKALEMIA Grade 4 to Grade 400
HYPERCALCEMIA Grade 0 to Grade 300
HYPERCALCEMIA Grade 0 to Grade 400
HYPERCALCEMIA Grade 1 to Grade 300
HYPERCALCEMIA Grade 1 to Grade 410
HYPERCALCEMIA Grade 2 to Grade 300
HYPERCALCEMIA Grade 2 to Grade 400
HYPERCALCEMIA Grade 3 to Grade 300
HYPERCALCEMIA Grade 3 to Grade 400
HYPERCALCEMIA Grade 4 to Grade 300
HYPERCALCEMIA Grade 4 to Grade 400
HYPOCALCEMIA Grade 0 to Grade 364
HYPOCALCEMIA Grade 0 to Grade 410
HYPOCALCEMIA Grade 1 to Grade 312
HYPOCALCEMIA Grade 1 to Grade 400
HYPOCALCEMIA Grade 2 to Grade 330
HYPOCALCEMIA Grade 2 to Grade 430
HYPOCALCEMIA Grade 3 to Grade 300
HYPOCALCEMIA Grade 3 to Grade 400
HYPOCALCEMIA Grade 4 to Grade 300
HYPOCALCEMIA Grade 4 to Grade 400
HYPERMAGNESEMIA Grade 0 to Grade 343
HYPERMAGNESEMIA Grade 0 to Grade 400
HYPERMAGNESEMIA Grade 1 to Grade 310
HYPERMAGNESEMIA Grade 1 to Grade 400
HYPERMAGNESEMIA Grade 2 to Grade 300
HYPERMAGNESEMIA Grade 2 to Grade 400
HYPERMAGNESEMIA Grade 3 to Grade 310
HYPERMAGNESEMIA Grade 3 to Grade 400
HYPERMAGNESEMIA Grade 4 to Grade 300
HYPERMAGNESEMIA Grade 4 to Grade 400
HYPOMAGNESEMIA Grade 0 to Grade 300
HYPOMAGNESEMIA Grade 0 to Grade 400
HYPOMAGNESEMIA Grade 1 to Grade 300
HYPOMAGNESEMIA Grade 1 to Grade 400
HYPOMAGNESEMIA Grade 2 to Grade 300
HYPOMAGNESEMIA Grade 2 to Grade 400
HYPOMAGNESEMIA Grade 3 to Grade 300
HYPOMAGNESEMIA Grade 3 to Grade 400
HYPOMAGNESEMIA Grade 4 to Grade 300
HYPOMAGNESEMIA Grade 4 to Grade 400
HYPOGLYCEMIA Grade 0 to Grade 311
HYPOGLYCEMIA Grade 0 to Grade 410
HYPOGLYCEMIA Grade 1 to Grade 300
HYPOGLYCEMIA Grade 1 to Grade 400
HYPOGLYCEMIA Grade 2 to Grade 300
HYPOGLYCEMIA Grade 2 to Grade 400
HYPOGLYCEMIA Grade 3 to Grade 300
HYPOGLYCEMIA Grade 3 to Grade 400
HYPOGLYCEMIA Grade 4 to Grade 300
HYPOGLYCEMIA Grade 4 to Grade 400
SecondaryNumber of Participants With Laboratory Abnormalities in Specific Thyroid Tests

Blood samples were collected for conducting specific thyroid test. Baseline is defined as evaluations or events that occur before the date and time of the first dose of study treatment. Baseline was defined as evaluations or events that occur before the date and time of the first dose of study treatment or evaluations on the same date and time of the first dose of study treatment were also considered as baseline evaluations.

Time frame:
From first dose and 30 days after last dose of study therapy (Up to approximately 11 months)
Reported as:
Count of participants · Participants
Number of Participants With Laboratory Abnormalities in Specific Thyroid Tests
ParticipantsNivolumab + Docetaxel + PrednisonePlacebo + Docetaxel + Prednisone
TSH > (Upper Limit of Normal) ULN9477
TSH > ULN with TSH <= Upper limit of Normal (ULN) AT Baseline7954
TSH > ULN with at Least One FT3/FT4 Test Value < LLN3920
TSH > ULN With All Other FT3/FT4 Test Values >= LLN6552
TSH > ULN with FT3/FT4 Test Missing2223
TSH < Lower Limit of Normal (LLN)155124
TSH < LLN with TSH >= LLN at Baseline12698
TSH < LLN with at Least One FT3/FT4 Test Value > ULN3314
TSH < LLN with all other FT3/FT4 Test Values <= ULN116106
TSH < LLN with FT3/FT4 Test Missing4524
SecondaryTime to Pain Progression as Assessed by Brief Pain Inventory-Short Form (BPI-SF)

The BPI-SF is an instrument to assess pain and includes severity and interference scores. BPI-SF is an 11-item self-report questionnaire designed to assess severity and impact of pain on daily function. Participants rate severity of pain at its "worst," "least," and "average" in last 24 hours using an 11-point numerical rating scale with anchors of "no pain" and "pain as bad. The participant's assessment of pain with BPI-SF Item number 3 (pain symptoms at their worst over the last 24 hours) form basis for analysis. Time to pain progression is time between date of randomization and date of first increase in worst pain intensity. Pain progression occurred if an increase in worst pain intensity of \>= 2 points is observed from baseline and maintained over 2 consecutive time periods. Baseline was evaluations or events that occur before date and time of first dose of study treatment or evaluations on same date and time of first dose of study treatment were also considered as baseline.

Time frame:
From randomization to 1st pain symptoms at their worst over the last 24 hours (Up to approximately 31 months
Reported as:
Median · months
Time to Pain Progression as Assessed by Brief Pain Inventory-Short Form (BPI-SF)
monthsNivolumab + Docetaxel + PrednisonePlacebo + Docetaxel + Prednisone
Time to Pain Progression as Assessed by Brief Pain Inventory-Short Form (BPI-SF)11.53 (10.28 to 13.57)12.42 (11.07 to 13.63)

Adverse events

Collected over All cause mortality was collected from randomization till death (up to approximately 52 months), Serious adverse events and non-serious adverse events were collected from first dose till 100 days post last dose (Up to approximately 27 months).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Nivolumab + Docetaxel + Prednisone259/514 (50.4%)256/510 (50.2%)479/510 (93.9%)
Placebo + Docetaxel + Prednisone227/516 (44%)242/510 (47.5%)494/510 (96.9%)
Most frequent serious events
Showing 10 of 325
Most frequent serious events
EventNivolumab + Docetaxel + PrednisonePlacebo + Docetaxel + Prednisone
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)19/51027/510
PneumoniaInfections and infestations18/5108/510
Febrile neutropeniaBlood and lymphatic system disorders17/51014/510
COVID-19Infections and infestations11/51013/510
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)10/51013/510
HaematuriaRenal and urinary disorders13/5102/510
PneumonitisRespiratory, thoracic and mediastinal disorders13/5103/510
AnaemiaBlood and lymphatic system disorders6/51012/510
DiarrhoeaGastrointestinal disorders12/5109/510
NeutropeniaBlood and lymphatic system disorders9/51010/510
Most frequent other events
Showing 10 of 43
Most frequent other events
EventNivolumab + Docetaxel + PrednisonePlacebo + Docetaxel + Prednisone
AlopeciaSkin and subcutaneous tissue disorders172/510178/510
DiarrhoeaGastrointestinal disorders175/510162/510
AnaemiaBlood and lymphatic system disorders157/510165/510
FatigueGeneral disorders141/510149/510
NauseaGastrointestinal disorders108/510134/510
AstheniaGeneral disorders113/510108/510
ConstipationGastrointestinal disorders112/510101/510
Oedema peripheralGeneral disorders90/510108/510
Decreased appetiteMetabolism and nutrition disorders96/51097/510
ArthralgiaMusculoskeletal and connective tissue disorders84/51097/510

Baseline characteristics

Age, Continuous
Age, Continuous(years)Nivolumab + Docetaxel + PrednisonePlacebo + Docetaxel + PrednisoneTotal
Mean68.9 ± 7.569.6 ± 8.169.2 ± 7.8
Sex: Female, Male
Sex: Female, Male(Participants)Nivolumab + Docetaxel + PrednisonePlacebo + Docetaxel + PrednisoneTotal
Female011
Male5145151029
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Nivolumab + Docetaxel + PrednisonePlacebo + Docetaxel + PrednisoneTotal
White333329662
Black or African American201535
Asian354580
Native Hawaiian or other pacific islander101
Chinese403878
Japanese334578
Asian other101
Other302757
Not Reported191635
Asian Indian213
08

Study locations

293 sites
  • Local Institution - 0305
    Mobile, Alabama 36608-1753, United States
  • Local Institution - 0012
    Anchorage, Alaska 99503, United States
  • Local Institution - 0293
    Tucson, Arizona 85724, United States
  • Local Institution - 0269
    Jonesboro, Arkansas 72401, United States
  • Local Institution - 0179
    Orange, California 92868, United States
  • Local Institution - 0055
    Rancho Mirage, California 92270, United States
  • Local Institution - 0260
    Redondo Beach, California 90277, United States
  • Local Institution - 0081
    Santa Monica, California 90404, United States
  • Local Institution - 0087
    Denver, Colorado 80211-5222, United States
  • Local Institution - 0190
    West Haven, Connecticut 06516-5907, United States
  • Local Institution - 0366
    Washington, District of Columbia 20010-3017, United States
  • Local Institution - 0196
    Hollywood, Florida 33021, United States
  • Local Institution - 0397
    Jacksonville, Florida 32256, United States
  • Local Institution - 0164
    Lakeland, Florida 33805, United States
  • Local Institution - 0181
    Orlando, Florida 32806, United States
  • Local Institution - 0285
    Pensacola, Florida 32503, United States
  • Local Institution - 0177
    Weston, Florida 33331, United States
  • Local Institution - 0117
    Atlanta, Georgia 30342, United States
  • Local Institution - 0126
    Marietta, Georgia 30060, United States
  • Local Institution - 0382
    Thomasville, Georgia 31792, United States
  • Local Institution - 0287
    Niles, Illinois 60714, United States
  • Local Institution - 0183
    Fort Wayne, Indiana 46804, United States
  • Local Institution - 0302
    Louisville, Kentucky 40202, United States
  • Local Institution - 0150
    Baltimore, Maryland 21201, United States
  • Local Institution - 0332
    Brandywine, Maryland 20613, United States
  • Local Institution - 0299
    Omaha, Nebraska 68130, United States
  • Local Institution - 0365
    East Brunswick, New Jersey 08816, United States
  • Local Institution - 0139
    Florham Park, New Jersey 07932, United States
  • Local Institution - 0300
    Albany, New York 12208, United States
  • Local Institution - 0028
    Port Jefferson Station, New York 11776, United States
  • Local Institution - 0333
    Columbus, Ohio 43210, United States
  • Local Institution - 0180
    Allentown, Pennsylvania 18103-6218, United States
  • Local Institution - 0074
    Bala-Cynwyd, Pennsylvania 19004, United States
  • Local Institution - 0292
    Pittsburgh, Pennsylvania 15232, United States
  • Local Institution - 0233
    Charleston, South Carolina 29414, United States
  • Local Institution - 0115
    Myrtle Beach, South Carolina 29572-4607, United States
  • Local Institution - 0149
    Germantown, Tennessee 38138, United States
  • Local Institution - 0286
    Austin, Texas 75251, United States
  • Local Institution - 0303
    Dallas, Texas 75251, United States
  • Local Institution - 0284
    Houston, Texas 77024-2843, United States
  • Local Institution - 0195
    Houston, Texas 77030-3721, United States
  • Local Institution - 0011
    San Antonio, Texas 78229, United States
  • The University of Texas Health Science Center at Tyler DBA UT Health East Texas Hope Cancer Center
    Tyler, Texas 75701, United States
  • Local Institution - 0110
    Seattle, Washington 98109, United States
  • Local Institution - 0289
    Spokane, Washington 99208, United States
  • Local Institution - 0129
    Mar del Plata, Buenos Aires B7602CBM, Argentina
  • Local Institution - 0061
    Pergamino, Buenos Aires B2700, Argentina
  • Local Institution - 0153
    Parana, Cordoba 5000, Argentina
  • Local Institution - 0393
    Rio Cuarto, Cordoba 5800, Argentina
  • Local Institution - 0083
    Viedma, RIO Negro 8500, Argentina
  • Local Institution - 0077
    Buenos Aires, 1280, Argentina
  • Local Institution - 0178
    Buenos Aires, 1426, Argentina
  • Local Institution - 0185
    Buenos Aires, C1012, Argentina
  • Local Institution - 0369
    La Rioja, F5300COE, Argentina
  • Local Institution - 0394
    San Juan, J5402DIL, Argentina
  • Local Institution - 0152
    Gosford, New South Wales 2250, Australia
  • Local Institution - 0091
    Lismore, New South Wales 2480, Australia
  • Local Institution - 0132
    Wahroonga, New South Wales 2076, Australia
  • Local Institution - 0127
    Westmead, New South Wales 2145, Australia
  • Local Institution - 0006
    South Brisbane, Queensland 4101, Australia
  • Local Institution - 0084
    Woolloongabba, Queensland 4102, Australia
  • Local Institution - 0010
    North Adelaide, South Australia 5006, Australia
  • Local Institution - 0379
    Ballarat, Victoria 3350, Australia
  • Local Institution - 0040
    Frankston, Victoria 3199, Australia
  • Local Institution - 0032
    Malvern, Victoria 3144, Australia
  • Local Institution - 0118
    Linz, Upper Austria 4020, Austria
  • Local Institution - 0038
    Salzburg, 5020, Austria
  • Local Institution - 0157
    Wien, 1020, Austria
  • Local Institution - 0131
    Wien, 1090, Austria
  • Local Institution - 0122
    Anderlecht, Brussel 1070, Belgium
  • Local Institution - 0121
    Brugge, 8000, Belgium
  • Local Institution - 0114
    Gent, 9000, Belgium
  • Local Institution - 0162
    Gent, 9000, Belgium
  • Local Institution - 0137
    Turnhout, 2300, Belgium
  • Local Institution - 0029
    Wilrijk, 2610, Belgium
  • Local Institution - 0097
    Belo Horizonte, Minas Gerais 30110022, Brazil
  • Local Institution - 0022
    Belo Horizonte, Minas Gerais 30130090, Brazil
  • Local Institution - 0100
    Curitiba, Parana 80530-010, Brazil
  • Local Institution - 0082
    Curitiba, Parana 80810050, Brazil
  • Local Institution - 0321
    Natal, Rio Grande Do Norte 59075-740, Brazil
  • Local Institution - 0058
    Ijui, Rio Grande Do Sul 98700-000, Brazil
  • Local Institution - 0056
    Porto Alegre, RIO Grande DO SUL 90035-903, Brazil
  • Local Institution - 0057
    Porto Alegre, Rio Grande Do Sul 90110-270, Brazil
  • Local Institution - 0063
    Porto Alegre, RS 90035-001, Brazil
  • Local Institution - 0086
    Campinas, SAO Paulo 13083 970, Brazil
  • Local Institution - 0096
    Sao Jose Do Rio Preto, Sao Paulo 15090-000, Brazil
  • Local Institution - 0059
    Santo Andre, SP 09060-650, Brazil
  • Local Institution - 0189
    Rio de Janeiro, 22250-905, Brazil
  • Local Institution - 0060
    Rio de Janeiro, 22793-080, Brazil
  • Local Institution - 0080
    Sao Paulo, 01321-001, Brazil
  • Local Institution - 0273
    Sao Paulo, 01327-0001, Brazil
  • Local Institution - 0328
    Sao Paulo, 05652- 900, Brazil
  • Local Institution - 0151
    Brampton, Ontario L6R 3J7, Canada
  • Local Institution - 0191
    Toronto, Ontario M2K 1E1, Canada
  • Local Institution - 0143
    Montreal, Quebec H2X 0A9, Canada
  • Local Institution - 0378
    Providencia, Metropolitana 1234, Chile
  • Local Institution - 0025
    Santiago de Chile, Metropolitana 0, Chile
  • Local Institution - 0377
    Santiago de Chile, Metropolitana 7500653, Chile
  • Local Institution - 0026
    Santiago, RM 7630372, Chile
  • Local Institution - 0027
    Vina del Mar, Valparaiso 2520598, Chile

Showing the first 100 of 293 sites across 28 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2020 to primary completion in Jun 2023, 39 months.

Results were first posted in Jul 2024, 1 year 1 month after primary completion.

Of 126 industry-sponsored phase 3 interventional studies under Prostatic Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 53. This study's 39 months is close to that.

Counting every sponsor, half of 265 studies reached it within 57 months; a quarter within 31 and three quarters within 100.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 20, 2019
First posted
Sep 23, 2019
StartActual
Feb 6, 2020
Primary completionActual
Jun 1, 2023
CompletionActual
Jun 25, 2024
Results first posted
Jul 22, 2024
Last update
Jun 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04100018
Responsible party
Sponsor
First posted
Sep 23, 2019
Start date
Feb 6, 2020
Primary completion
Jun 1, 2023
Completion
Jun 25, 2024
Results posted
Jul 22, 2024
Last update
Jun 12, 2025

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nivolumab

Start the discussion